Researchers assessed the extent to which pain severity influenced prognosis in patients with newly diagnosed head and neck cancer.
After failure of platinum-based chemotherapy, the tyrosine kinase inhibitor (TKI) afatinib significantly improved progression-free survival in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Human papillomavirus (HPV)-positive oropharyngeal cancer may not require neck surgery after receiving radiation therapy and chemo.
Patients with advanced laryngeal cancer appear to have better survival if they are treated with surgery than with nonsurgical chemoradiation.
Although mutations in a gene dubbed the "guardian of the genome" are recognized as being associated with more aggressive cancers, evidence suggests that the deleterious health effects of the mutated gene may in large part be due to other genetic abnormalities.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|